Kopp Family Office LLC Decreases Stake in Viridian Therapeutics, Inc. $VRDN

Kopp Family Office LLC trimmed its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 10.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 173,173 shares of the company’s stock after selling 20,657 shares during the quarter. Viridian Therapeutics makes up about 3.4% of Kopp Family Office LLC’s portfolio, making the stock its 9th largest holding. Kopp Family Office LLC owned about 0.18% of Viridian Therapeutics worth $5,389,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in VRDN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Viridian Therapeutics by 1.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after buying an additional 876 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Viridian Therapeutics by 33.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock valued at $16,595,000 after acquiring an additional 310,998 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Viridian Therapeutics by 12.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock valued at $1,760,000 after acquiring an additional 14,788 shares during the last quarter. Envestnet Asset Management Inc. acquired a new stake in shares of Viridian Therapeutics during the 2nd quarter valued at $187,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Viridian Therapeutics by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,740,614 shares of the company’s stock valued at $24,337,000 after acquiring an additional 20,089 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on VRDN shares. Evercore reaffirmed an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Wall Street Zen lowered Viridian Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Wedbush reaffirmed an “outperform” rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, March 11th. William Blair assumed coverage on shares of Viridian Therapeutics in a report on Wednesday, December 3rd. They issued an “outperform” rating for the company. Finally, Truist Financial cut their target price on shares of Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $42.21.

Insider Buying and Selling

In related news, insider Jennifer Tousignant sold 2,272 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total value of $70,795.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.58% of the stock is owned by insiders.

Viridian Therapeutics Stock Up 4.3%

Shares of NASDAQ:VRDN opened at $28.35 on Thursday. The firm has a market cap of $2.90 billion, a P/E ratio of -8.62 and a beta of 1.00. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $34.29. The business has a fifty day simple moving average of $29.93 and a 200 day simple moving average of $27.73.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $15.75 million. Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. Analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.